ARTV — Artiva Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817241 ·
Last close
$3.86
Market Cap
$190.81M
52W High
$14.53
52W Low
$2.96
ADV30
1,112,928
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -31,954,000 | -28,822,000 | 342,975,000 | 61,234,000 | 22,259,000 |
| Jun 2026 | 0 | — | -26,890,000 | -25,005,000 | 368,633,000 | 301,454,000 | 21,131,000 |
| Mar 2026 | 0 | — | -24,430,000 | -23,516,000 | 105,955,000 | 20,955,000 | 18,108,000 |
| Dec 2025 | 0 | — | -21,932,000 | -20,772,000 | 130,940,000 | 26,701,000 | 20,970,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,478,000
Investing CF
$-162,763,000
Financing CF
$283,010,000
CapEx
$-2,123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.02
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-407,892,000
Inventory
—
Receivables
$21,000
ST Investments
$257,867,000
EBIT TTM
$-105,206,000
Pretax Income TTM
$-98,115,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -89,810,000 | -83,865,000 | 130,940,000 | 20,970,000 | 109,970,000 | -76,751,000 |
| Dec 2024 | 251,000 | -67,282,000 | -58,179,000 | 209,581,000 | 22,940,000 | 186,641,000 | -55,032,000 |
| Dec 2023 | 33,492,000 | -30,671,000 | -32,766,000 | 105,114,000 | 267,129,000 | -162,015,000 | -47,430,000 |
| Dec 2022 | 4,931,000 | -59,829,000 | -60,976,000 | 133,054,000 | 273,750,000 | -140,696,000 | -50,829,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-90,821,000
OpCashFlow TTM
—
Assets (Latest)
$368,633,000
Forward EPS
$-1.87
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $3.77 · call oi: 6,595 · put oi: 24
Expected Move to 2026-12-18:
±$1.22
(32.36%) —
implied range
$2.55 –
$4.99
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGEN | COMPUGEN LTD | $191.34M | $2.02 | — |
| IKT | Inhibikase Therapeutics, Inc. | $193.57M | $1.38 | — |
| DTIL | PRECISION BIOSCIENCES INC | $196.95M | $7.05 | — |
| PALI | PALISADE BIO, INC. | $181.07M | $1.01 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $206.36M | $0.82 | — |
News headlines (Yahoo Finance, 1h cache)
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
2026-10-27 17:58 · Yahoo
Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce?
2026-10-27 16:22 · Yahoo
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
2026-10-27 15:44 · Yahoo
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
2026-10-27 14:08 · Yahoo
Artiva Biotherapeutics stock tumbles after halting drug trial
2026-10-27 12:40 · Yahoo
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
2026-10-27 11:30 · Yahoo
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
2026-10-01 11:30 · Yahoo
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
2026-09-23 11:30 · Yahoo
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-17 12:00 · Yahoo
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
2026-09-08 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.